In patients with NPM1+ AML (n = 137, including patients with concomitantly mutated FLT3), median OS and RFS were significantly prolonged in the treatment arm (47 months vs 16 months, p = 0.038 for OS; 23 months vs 7 months, p = 0.005 for RFS) albeit with trends toward converging outcomes at late time points.26 The prolongation of median OS was most pronounced among NPM1+ patients positive for measurable residual disease (MRD) after initial chemotherapy (induction ± consolidation). Here, FLT3 is linked to acute myeloid leukemia.